- Sun Pharma's Q3FY26 consolidated net profit rose 16% to Rs 3,369 crore
- Revenue increased 13.5% to Rs 15,521 crore compared to last year
- EBITDA grew 23.4% to Rs 4,949 crore with a margin of 29.3%
Sun Pharmaceutical Industries Ltd. reported a 16% year-on-year rise in the consolidated net profit to Rs. 3,369 crore in Q3FY26 from Rs. 2,903 crore. Revenue was at Rs. 15,521 crore compared with Rs. 13,676 crore, up 13.5%. Earnings before interest, taxes, depreciation and amortisation was reported to be Rs 4,949 crore versus Rs. 4,009 crore, up 23.4%. Margin is seen at 29.3% versus 31.9%.
Sun Pharmaceutical Industries Q3FY26 results (Cons, YoY)
- Profit Up 16% at Rs 3,369 crore versus Rs 2,903 crore.
- Revenue Up 13.5% at Rs 15,521 crore versus Rs 13,676 crore.
- Ebitda Up 23.4% at Rs 4,949 crore versus Rs 4,009 crore.
- Margin at 29.3% versus 31.9%.
Sun Pharmaceutical Share Price On Sunday
Shares of Sun Pharmaceutical Industries closed 0.36% higher at Rs. 1,595.30 crore on NSE, compared to a 0.39% decrease in the Nifty index on Sunday.
Also Read: Q3 Results LIVE Updates: IDFC First Bank, Sun Pharma, And CDSL Quarterly Earnings Today
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
